 This is a double-blind neither the researchers nor the participants know what treatment the participant is receiving, randomized study drug assigned by chance, placebo-controlled an inactive substance; a pretend treatment with no drug in it that is compared in a clinical trial with a drug to test if the drug has a real effect, and single-center study. The study will consist of Screening Period 2 to 21 days prior to participants dose administration, Double-blind Treatment Period single dose of JNJ-49122944 or placebo on Day 1, and Safety Follow-up Period 4 to 7 days after discharge. The total duration of participation for each participant, including screening, will be up to approximately 4 weeks. Blood samples will be collected for assessment of pharmacokinetic parameters. Participants safety will be monitored throughout the study. 